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Targeted drug activation at selected site promises reduced toxicity and enhanced efficacy. We propose to investigate and validate a bipartite drug delivery-activation system that employs selective tumor vascular targeted induction of endogenous coagulation protease cascade followed by administration of protease-activated prodrug. The activation of coagulation cascade and tumor vascular thrombosis as well as the following activation of the thrombolytic pathways led to explosive amplification of serine protease cascades and local proteolytic activity within the tumor vasculature. This tumor specific proteolytic activity is exploited for targeted local prodrug activation. The combination treatment of selective tumor vascular thrombosis and protease-activated prodrug demonstrated profound synergism. This coordinated attack on tumors resulted in complete tumor eradication in multiple drug resistant rodent and human tumor models with no apparent toxicity.
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Introduction
Targeted drug activation at selected sites promises reduced toxicity and enhanced efficacy. We propose to investigate and validate a bipartite drug delivery-activation system that employs selective tumor vascular targeted induction of endogenous coagulation protease cascade followed by administration of a protease-activated prodrug1. The efficacy of this strategy has been demonstrated by a fibronectin motif and Tissue Factor extracellular domain fusion protein that specifically activates coagulation on the tumor vascular endothelial surface when certain integrins, such as αvβ3 and α5β1, are expressed and exposed. The activation of the coagulation cascade and tumor vascular thrombosis as well as subsequent activation of thrombolytic pathways leads to the explosive amplification of serine protease cascades and local proteolytic activity within the tumor vasculature. This tumor specific proteolytic activity has also been exploited for targeted local prodrug activation. The combination treatment of selective tumor vascular thrombosis and protease-activated prodrug demonstrated a profound synergism. Indeed, more robust and sustained tumor vascular thrombosis was observed compared to selective tumor vascular thrombosis alone. The activation of local tumor vascular thrombosis substantially increased prodrug activation and retention in tumors. Importantly, the activated prodrug eliminated the remaining tumor cells at the rim of tumors that do not depend on neo-angiogenesis for survival. This coordinated attack on tumors resulted in complete tumor eradication in multiple drug resistant rodent and human tumor models with no apparent toxicity. This synergistic targeted activation of coagulation and prodrug possesses interchangeable targeting potentials with different tumor vascular specific molecules and thus may represent a general therapeutic strategy for breast cancer therapy.
Body
The funding from this synergistic grant provided critical support for us to pursue research in translational medicine and experimental therapeutics in the area of breast cancer. We have made significant progress during the first year of this grant.
Targeted drug activation at selected site promises reduced toxicity and enhanced efficacy. We describe here a bipartite drug delivery-activation system that employs selective tumor vascular targeted induction of endogenous coagulation protease cascade followed by administration of protease-activated prodrug. The efficacy of this strategy is demonstrated by a integrin targeted STVT that specifically activates coagulation on the tumor vascular endothelial surface. Annual Report Cheng Liu, M.D., Ph.D The activation of coagulation cascade and tumor vascular thrombosis as well as the following activation of the thrombolytic pathways led to explosive amplification of serine protease cascades and local proteolytic activity within the tumor vasculature. This tumor specific proteolytic activity is exploited for targeted local prodrug activation. The combination treatment of selective tumor vascular thrombosis and protease-activated prodrug demonstrated profound synergism. More robust and sustained tumor vascular thrombosis are observed compared to selective tumor vascular thrombosis alone. The activation of local tumor vascular thrombosis substantially increased prodrug activation and retention in tumors. Importantly, the activated prodrug eliminated the remaining tumor cells at the rim of tumors that are not dependent on neoangiogenesis for survival. This coordinated attack on tumors resulted in complete tumor eradication in multiple drug resistant rodent and human tumor models with no apparent toxicity. This synergistic targeted activation of coagulation and prodrug has interchangeable targeting potentials with different tumor vascular specific molecules and thus my represent a general therapeutic strategy for cancer therapy. We have completed the design and production of integrin directed STVT and proceeded to the in vivo testing of this STVT. In addition to integrin targeted STVT, proteases associated with angiogenic endothelial surfaces are targeted with legumain targeting STVT and PSMA targeted targeting STVT (there are new reports indicate PSMA is widely expressed in angiogenic tumor vascular endothelial cells including breast cancers) were also constructed and produced. These STVTs are being examined for effective tumor infarction in vivo. These proteases are expressed on the surface of tumor endothelial cells and will be used to target STVT using small molecule inhibitor as targeting entity.
Design and chemical synthesis of a protease-activated prodrug.
(Month 1st to 12th) Annual Report Cheng Liu, M.D., Ph.D In addition to doxorubicin based prodrug, two paclitaxel based prodrugs that are activated by proteases in the coagulation cascade are prepared. They take advantage of a facile chemistry licking the substrate peptides to the C10 position. These drugs are water soluble compare to paclitaxel parent compound.
One of the key discovery in the course of last year is that factor VII can cross the leaky tumor vasculature and are forming TF:VIIa complex on tumor cell surface.
Factor VIIa is stained with a rat anti-mouse VIIa antibody in 4T1 mammary carcinoma grown in Balb c mice. The green represent VIIa on tumor cell surface. Therefore, TF:VIIa comples is active in the tumor microenvironment outside the blood vessel. This explains the substantial single agent efficacy of TF:VIIa activated prodrug in these models. We are in the process to assess whether Xa and thromobin can exit the tumor vasculature. Annual Report Cheng Liu, M.D., Ph.D The doxorubicn based prodrug with LTPR substrate recognition sequence is properly activated by VIIa and demonstrated significant growth inhibition in 4T1 mouse mammary carcinoma model given at 10 umol/kg daily. Doxorubicin is ineffective at MTD in this model.
We are in the process to evaluate this compound and the paclitaxel based compound in additional syngeneic and xenograph models of mammary carcinoma.
3. In vivo efficacy of combined selective tumor vascular thrombosis and a protease-activated prodrug. 
Reportable Outcomes
1. Characterizing the molecular mechanism of STVT action (reported in Molecular Cancer Therapeutics).
2. Prove of principle of tumor microenvironment activated prodrugs and in vivo demonstration of prodrug efficacy against drug resistant breast cancers (reported in Cancer Research). Finding of TF:VIIa complex formation in tumor microenvironment and activation of prodrug. Demonstration of single agent efficacy of TF:VIIa activated prodrug.
3. Synergism between integrin targeted directed STVT and prodrug. 4. A PCT is filed to protect IP generated from studies supported by this grant (see appendix). This patent covers the prodrug side of the technology.
Patent for STVT is awarded (see appendix)
. Although the initial filing of this patent precedes the award of this grant, the data generated with the support of this grant is instrumental provide additional support to obtain patent. Unfortunately, you can not add new acknowledgement into the patent despite adding new data to support the original invention.
6. The technology developed from this grant is licensed by a commercial entity from TSRI and is undergoing further preclinical development.
Conclusions
The local tumor microenvironment differs greatly from that of other tissues. One key character is that it is enriched in proteolytic activity. Cell surface proteases, such as legumain and PSMA, play important role in cancer progression such as invasion/metastasis and angiogenesis. The coagulation cascade is also activated in tumor vasculature. The over-expression of these cell surface proteases are ideal physical as well as functional targets for cancer therapy. It can serve to target thrombogens to infarct tumors and also to activate prodrugs in the tumor microenvironment as demonstrated by data generated with the support of this grant. 
Statement of Government Rights
The invention was made with the support of a grant from the Government of the United States of America (CDMRP Grant Numbers W81XWH-05-1-0091 and W81XWH-05-1-0318 from the Department of Defense). The Government may have certain rights to the invention.
Field of the Invention
The present invention relates to methods for treating and/or inhibiting tumor cell invasion, metastasis and/or angiogenesis as well as increasing apoptosis in cancer cells by administering asparaginyl endopeptidase inhibitors. In some embodiments, the invention relates to inhibitors of proteases that are expressed under the hypoxic conditions of the tumor microenvironment. In other embodiments, the invention relates to prodrug agents that become activated by the proteases that are expressed in the tumor microenviroment.
The prodrugs become active within the tumor microenvironments of primary and metastatic tumor sites, for example, at the surface of, cancerous cells and tumor stomal cells that express proteases.
Background of the Invention
The following description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is
Annual Report Cheng Liu, M.D., Ph.D prior art, or relevant, to the presently described inventions, or that any publication or document that is specifically or implicitly referenced is prior art. Current cancer treatments generally involve the use of surgery, radiation therapy, and/or chemotherapy. However, these treatments all involve serious side effects. For example, surgery can be complicated by bleeding, damage to internal organs, adverse reactions to anesthesia or other medicines, pain, infection, and slow recovery. Radiation therapy can damage normal cells and can cause fatigue. For many people, chemotherapy is the best option for controlling their cancer. However, chemotherapy can also damage normal cells such as bone marrow and blood cells, cells of the hair follicles, and cells of the reproductive and digestive tracts. Chemotherapy can also cause nausea, vomiting,
Annual Report Cheng Liu, M.D., Ph.D constipation, diarrhea, fatigue, changes to the nervous system, cognitive changes, lung damage, reproductive and sexual problems, liver, kidney, and urinary system damage, and, especially with the use of the chemotherapeutic agent doxorubicin, heart damage. Longterm side effects of chemotherapy can include permanent organ damage, delayed development in children, nerve damage, and blood in the urine. Thus, the use of the chemotherapy for cancer treatment is not without serious side effects.
Most agents currently administered to a patient are not targeted to the site where they are needed, resulting in systemic delivery of the agent to cells and tissues of the body where the agent is unnecessary, and often undesirable. Such systemic delivery may result in adverse side effects, and often limits the dose of an agent (e.g., cytotoxic agents and other anti-cancer agents) that can be administered. Accordingly, a need exists for agents and methods that specifically target cancerous cells and tissues.
Thus, it would be desirable to be able to direct various agents to cancer cells and to the tumor microenvironment so as to be able to decrease the dosage of the agents given and to decrease the systemic toxicity and side effects associated with these agents.
Summary of the Invention
According to the invention, the tumor microenvironment creates conditions that induce expression of certain genes, including proteases that are active almost exclusively in the tumor microenvironment. For example, an unexpectedly high level expression of asparaginyl endopeptidases, including legumain, is present in a wide variety of cancer cells, particularly those involved in metastasis. Other proteases that are active in the tumor microenvironment include prostate specific membrane antigen (PSMA)(a carboxypeptidase), fibroblast activation protein (FAP) (a serine peptidase), cathepsin B (a cysteine protease), cathepsin X (a cysteine protease), urokinase-type plasminogen activator (uPA)(a serine protease), tissue factor VIIa (TF VIIa)(a serine protease), matriptase (a membrane-bound serine protease) and Factor XIII. As described herein, tumor-specific protease expression occurs early in the development of cancer cell invasion, just as metastasis begins, and under the hypoxic conditions associated with invasive tumor growth.
Moreover, legumain is directly involved in and actually inhibits the cascade of activities Another aspect of the invention is a protease-activated prodrug that is tumoricidal in vivo, wherein the protease is a protease that is expressed in the tumor microenvironment (e.g., under the hypoxic conditions of tumor microenvironments). These protease-activated prodrugs have reduced side effects and toxicity relative to currently available chemotherapeutics. While the present prodrugs are useful for treating cancer, they are also useful to treat other conditions and cellular environments that express proteases. For example, certain non-transformed cells support tumor growth and invasion and, as described herein also express proteases when present in the tumor microenvironment.
Hence, the present prodrugs can be used to target and kill not only cancer cells but also the cells that support tumor growth and tumor cell metastasis.
A prodrug compound of the invention includes a drug molecule linked to a peptide, wherein the peptide has an amino acid sequence that is specifically recognized by a protease expressed in a tumor microenvironment. Thus, the peptide includes at least two linked amino acids, wherein at least one of the two linked amino acids is an amino acid that is specifically recognized by a tumor-specific protease and forms part of a cleavage site for the protease. For example, legumain is a protease that is specifically expressed in tumor cells and cells that support tumor growth and metastasis (e.g. tumor associated macrophages). Legumain is an asparaginyl protease that specifically recognizes asparagine-containing peptides and cleaves peptides that contain asparagine (Asn). Some of the prodrugs of the invention are therefore designed to be activated by legumain.
Legumain cleaves the peptide of the present prodrugs at the site of the Asn to generate an active drug from the prodrug. Prior to cleavage, the prodrug is substantially non-toxic to normal animal cells, whereas after cleavage, the drug is an active drug that can have a beneficial effect upon an animal to which it is administered.
Prodrugs of the invention have the general structure: R 1 -peptide-drug wherein R 1 is hydrogen, a hydrophilic group, a hydrophobic group, a photosensitizing agent, a label or an amino protecting group; and drug is any therapeutic agent. In some embodiments, the R 1 groups of the present prodrugs are not hydrophobic 
PEG-TSGP-S-linker-Taxol Prodrug-6 PEG-TSGP-S-PEG-linker-Taxol Prodrug-7
Prodrug-1 and prodrug-2 are activated by serine protease TF VIIa. Prodrug-3, prodrug-4 and prodrug-5 are activated by legumain. Additional legumain prodrugs include
, whose structures are shown in FIG. 9A . In some instances, the prodrugs of the invention do not include LEG-2 or LEG-3, because the inventor has filed a separate application on these compounds. Prodrug-6 and prodrug-7 are activated by fibroblast activation protein (FAP).
The drug employed is any drug whose action is diminished or blocked by attachment of a peptide to the drug. The ability of the drug to enter cells is diminished, inhibited or blocked by attachment of the peptide and hydrophilic groups. Such hydrophilic groups are generally included to facilitate water-solubility and cell impermeability. Hydrophilic groups are generally attached to the peptide so that the function of the drug is not inhibited or blocked by the hydrophilic group once the peptide is cleaved from the prodrug to yield the drug.
W81XWH-07-1-0389
Annual Report Cheng Liu, M.D., Ph.D In some embodiments, the drug can be a cytotoxin or a photosensitizing agent.
Such a cytotoxin can be aldesleukin, 5-aminolevulinic acid, bleomycin sulfate, camptothecin, carboplatin, carmustine, cisplatin, cladribine, lyophilized cyclophosphamide, non-lyophilized cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethyistilbestrol, epoetin alfa, esperamycin, etidronate, etoposide, filgrastim, floxuridine, fludarabine phosphate, fluorouracil, goserelin, granisetron hydrochloride, idarubicin, ifosfamide, immune globulin, interferon alpha-2a, interferon alpha-2b, leucovorin calcium, leuprolide, levamisole, mechiorethamine, medroxyprogesterone, melphalan, methotrexate, mitomycin, mitoxantrone, octreotide, ondansetron hydrochloride, paclitaxel, pamidronate, pegaspargase, plicamycin, protoporphyrin IX, sargramostim, streptozocin, taxol, thiotepa, teniposide, vinblastine, or vincristine. In some embodiments, the drug is doxorubicin, 5-aminolevulinic acid, protoporphyrin IX, taxol or paclitaxel.
In one embodiment, the prodrug is activated by asparaginyl proteases (e.g., legumain) and has a peptide amino acid sequence comprising SEQ ID NO:3:
R 1 is hydrogen, a hydrophilic group, a hydrophobic group, a photosensitizing agent, a label or an amino protecting group; n is an integer of about 0 to about 50; Xaa1 and Xaa2 are separately any amino acid; Xaa3 is either nothing or an amino acid that has no substantial effect on the activity of the drug; and the drug employed is a drug whose action is diminished or blocked by attachment of a peptide to the drug.
In some embodiments, the R 1 groups of the present prodrugs are not hydrophobic groups or labels. For example, when cytotoxic drugs are part of the prodrug, a hydrophilic group is preferably used for R 1 to limit cell uptake by non-target cells.
Examples of peptide sequences that may be used in the prodrugs of the invention include amino acid sequence Asn-Leu, Ala-Asn-Leu, Thr-Asn-Leu, Ala-Ala-Asn-Leu (SEQ ID NO:5), Ala-Thr-Asn-Leu (SEQ ID NO:6), and Boc-Ala-Ala-Asn-Leu (SEQ ID NO:4). Examples of prodrugs provided by the invention include Boc-Ala-Ala-Asn-Leu- As described herein a hydrophilic R 1 group (sometimes abbreviated herein as "Hyd") facilitates prodrug and inhibitor water solubility and inhibits cell uptake and tissue retention of the prodrug before activation and of the inhibitor before binding to a protease (e.g. the legumain:integrin complex). A variety of hydrophilic protecting groups can be utilized. Hydrophilic R 1 groups of the invention can be sugars (monosaccharides and disaccharides), dicarboxylic acids (e.g., succinate, malate, fumarate, oxaloacetate, citrate, isocitrate), glycans, polyalkylene oxides, lower alkyl carboxylates, carboxyalkyls, carboxyalkylene carboxylates, charged amino acids (e.g., any of the hydrophilic, acidic, basic and polar amino acids described herein) and the like. In some embodiments the protecting group is a hydrophilic amino protecting group. Specific examples of R 1 groups that can be used include glucuronide, succinyl, polyethylene glycol (PEG) or glutathione.
Hydrophobic groups can used if cellular uptake of the drug is desired. Hydrophobic groups that can be used include those listed herein.
The invention also provides a protease inhibitor having including formulae III, IV, V or VI:
wherein R 1 is hydrogen, a hydrophilic group, a hydrophobic group, a photosensitizing agent, a label or an amino protecting group; n is an integer of about 2 to about 5; each Xaa4 and Xaa5 is an amino acid or an amino acid mimetic; AEPI-1 is R 1 -Ala-Ala-AzaAsn-(S,S)-EPCOOEt, a compound of the structure:
AEPI-2 is R 1 -Ala-Ala-AzaAsn-CH=CH-COOEt, for example, a compound of the structure:
AEPI-3 is R 1 -Ala-Ala-AzaAsn-CH=CH-COOBzl, for example, a compound of the structure:
AEPI-4 is R 1 -Ala-Ala-AzaAsn-CH=CH-CON(CH 3 )Bzl, for example, a compound of the structure:
AEPI-5 is N-acetyl-Ala-Ala-AzaAsn-(S,S)-EPCOOEt, a compound of the structure: wherein R 1 is hydrogen, a hydrophilic group, a hydrophobic group, a photosensitizing agent, a label or an amino protecting group; Ep is epoxy; Et is ethyl; and Bzl is benzyl.
Inhibitors of PSMA that can be used in the invention include the following:
wherein R 1 is hydrogen, a hydrophilic group, a hydrophobic group, a photosensitizing agent, a label or an amino protecting group. Cathepsin B inhibitors useful in the invention include the following:
wherein R 1 is hydrogen, a hydrophilic group, a hydrophobic group, a photosensitizing agent, a label or an amino protecting group.
Cathepsin X inhibitors useful in the invention include the following:
Urokinase-type plasminogen activator (uPA) inhibitors useful in the invention include the following:
Tissue factor VIIa (TF VIIa) inhibitors useful in the invention include the following: wherein R 1 is hydrogen, a hydrophilic group, a hydrophobic group, a photosensitizing agent, a label or an amino protecting group.
Annual Report Cheng Liu, M.D., Ph.D In some embodiments, the inhibitor is linked to a photosensitizing agent. While any available photosensitizing agent can be used (e.g., any of the photosensitizing agents contemplated for use with the present prodrugs), specific examples of photosensitizing agents include chlorin e6 and aluminum phthalocyanine tetrasulfonate (AlPcS4). Examples of inhibitors with chlorin e6 and AlPcS4 are shown below. Any convenient amino protecting group available in the art can be used in the invention including, for example, carbobenzyloxy (Cbz), tert-butyloxycarbonyl (BOC), 9-fluorenylmethyloxycarbonyl (FMOC) and benzyl groups.
A variety of labels can be used with the inhibitors of the invention to generate imaging agents or reagents for detection of cancer. Such labels can be fluorophores, radioisotopes, metals, enzymes, enzyme substrates, luminescent moieties, and the like.
One example of a label that may used is gadolinium or a gadolinium complex. For example, the following gadolinium complex can be used as a label:
In other embodiments, the legumain inhibitor can be cystatin, stefin, a peptide including the sequence Ala-Leu-β-Asn-Ala-Ala (SEQ ID NO:15) or an antibody that inhibits legumain activity.
Another aspect of the invention is a pharmaceutical composition that includes at least one of the prodrug compounds of the invention or at least one of the protease inhibitors of the invention and a pharmaceutically acceptable carrier. In some embodiments, the carrier is a liposome. Combinations of the present prodrug compounds and/or protease inhibitors can also be included in the compositions of the invention.
Another aspect of the invention is a method of detecting and treating cancer in a mammal, comprising administering to the mammal an inhibitor of the invention, wherein R 1 is a label, to detect whether the mammal has cancer and to detect which type of tumor specific protease is associated with the cancer, and administering a prodrug of the invention to treat the cancer, wherein the prodrug has a cleavage site fot the tumor specific protease associated with the cancer.
Another aspect of the invention is a method for treating a mammal having, or suspected of having cancer. The method includes administering to the mammal a prodrug compound and/or a protease inhibitor of the invention in amounts and at intervals effective The invention also provides a method for inhibiting cancer metastasis and/or tumor cell invasion in an animal, including administering a protease inhibitor compound and/or prodrug of the invention to the animal in amounts and at intervals effective to prevent, reduce, or eliminate cancer metastasis and/or tumor cell invasion.
The invention also provides a method for inhibiting cell migration in an animal that includes administering a protease inhibitor compound and/or prodrug of the invention to the animal in amounts and at intervals effective to prevent, reduce, or eliminate cancer cell migration.
The invention also provides a method of killing a cell in a tissue, including contacting the cell with a prodrug of the invention in amounts and at intervals effective to kill the cell, wherein the tissue includes cells that express legumain.
The invention also provides a method for treating cancer in animal that includes administering to the animal a protease inhibitor compound or a prodrug of the invention in amounts and at intervals effective to prevent, reduce, or eliminate one or more symptoms of cancer in the animal.
The invention also provides a method for inhibiting cancer metastasis in a tissue that includes contacting the tissue with a protease inhibitor compound or prodrug of the Annual Report Cheng Liu, M.D., Ph.D invention in amounts and at intervals effective to prevent, reduce, or eliminate cancer metastasis.
The invention also provides a method for inhibiting cancer cell migration in a tissue that includes contacting the tissue with a protease inhibitor compound or prodrug of the invention in amounts and at intervals effective to prevent, reduce, or eliminate cancer cell migration.
The invention also provides a method for treating inflammation in an animal, which includes administering to the mammal a protease inhibitor compound or prodrug of the invention in amounts and at intervals effective to prevent, reduce, or eliminate one or more symptoms associated with inflammation.
The invention also provides a method for delivering a drug to a cell in a tumor microenvironment of a mammal, which includes administering to the mammal an effective amount of a prodrug of the invention.
The invention also provides a method for diagnosing cancer in a tissue that includes contacting the tissue with of an agent that specifically binds to a protease that is expressed in a tumor microenvironment, and detecting whether the agent binds to the tissue. The invention also provides a method for diagnosing cancer in an animal that includes administering to the animal an agent that specifically binds to a protease that is expressed in a tumor microenvironment, and detecting whether the agent accumulates in a tissue. For example, the protease can be selected from the group legumain, PSMA, FAP, Cathepsin B, Cathepsin X, uPA, TF VIIa, matriptase and Factor XIII. These methods can further include diagnosing the patient as having or not having cancer and monitoring the progression of a cancer.
The invention also provides a method for imaging a tissue that expresses a protease.
For example, the protease can be selected from the group legumain, PSMA, FAP, Cathepsin B, Cathepsin X, uPA, TF VIIa, matriptase and Factor XII. The method includes contacting a test tissue suspected of expressing the protease with of an agent that specifically binds to the protease, and detecting whether the agent binds to the test tissue.
The method can further include quantifying and comparing amounts of the agent bound to the test tissue with amounts of the agent bound to a control tissue that does not express the protease. The agent can be protease inhibitor-imaging agent or a labeled antibody that specifically binds to the protease.
In another embodiment, the prodrug and inhibitor compounds of the invention can be used for the manufacture of a medicament useful for treating diseases such as cancer.
